These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 16291747)

  • 1. BCR-ABL regulates phosphatidylinositol 3-kinase-p110gamma transcription and activation and is required for proliferation and drug resistance.
    Hickey FB; Cotter TG
    J Biol Chem; 2006 Feb; 281(5):2441-50. PubMed ID: 16291747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bcr-Abl regulates osteopontin transcription via Ras, PI-3K, aPKC, Raf-1, and MEK.
    Hickey FB; England K; Cotter TG
    J Leukoc Biol; 2005 Jul; 78(1):289-300. PubMed ID: 15857938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
    Wilson MB; Schreiner SJ; Choi HJ; Kamens J; Smithgall TE
    Oncogene; 2002 Nov; 21(53):8075-88. PubMed ID: 12444544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
    Burchert A; Wang Y; Cai D; von Bubnoff N; Paschka P; Müller-Brüsselbach S; Ottmann OG; Duyster J; Hochhaus A; Neubauer A
    Leukemia; 2005 Oct; 19(10):1774-82. PubMed ID: 16136169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Kinetics of proliferation, differentiation and transcription of genes regulating apoptosis in cultured human BCR/ABL+ Ph+-cells].
    Akhlynina TV; Gerasimova LP; Sarkisian GP; Borovkova TV; Dukhovenskaia EA; Manakova TE; Naĭdenova NM; Timofeev AM; Grineva NI
    Tsitologiia; 2007; 49(10):889-900. PubMed ID: 18074781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of Raf kinase inhibitor protein expression by Bcr-Abl contributes to chronic myelogenous leukemia proliferation.
    Takemura T; Nakamura S; Yokota D; Hirano I; Ono T; Shigeno K; Fujisawa S; Ohnishi K
    J Biol Chem; 2010 Feb; 285(9):6585-94. PubMed ID: 20028985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway.
    Skorski T; Bellacosa A; Nieborowska-Skorska M; Majewski M; Martinez R; Choi JK; Trotta R; Wlodarski P; Perrotti D; Chan TO; Wasik MA; Tsichlis PN; Calabretta B
    EMBO J; 1997 Oct; 16(20):6151-61. PubMed ID: 9321394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation.
    Raitano AB; Halpern JR; Hambuch TM; Sawyers CL
    Proc Natl Acad Sci U S A; 1995 Dec; 92(25):11746-50. PubMed ID: 8524841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular biology of chronic myeloid leukemia.
    Maru Y
    Int J Hematol; 2001 Apr; 73(3):308-22. PubMed ID: 11345196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL.
    Horita M; Andreu EJ; Benito A; Arbona C; Sanz C; Benet I; Prosper F; Fernandez-Luna JL
    J Exp Med; 2000 Mar; 191(6):977-84. PubMed ID: 10727459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.
    Chu S; Holtz M; Gupta M; Bhatia R
    Blood; 2004 Apr; 103(8):3167-74. PubMed ID: 15070699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies.
    Warmuth M; Danhauser-Riedl S; Hallek M
    Ann Hematol; 1999 Feb; 78(2):49-64. PubMed ID: 10089019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EPS8 regulates proliferation, apoptosis and chemosensitivity in BCR-ABL positive cells via the BCR-ABL/PI3K/AKT/mTOR pathway.
    Huang R; Liu H; Chen Y; He Y; Kang Q; Tu S; He Y; Zhou X; Wang L; Yang J; Wu A; Li Y
    Oncol Rep; 2018 Jan; 39(1):119-128. PubMed ID: 29192326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells.
    Andreu EJ; Lledó E; Poch E; Ivorra C; Albero MP; Martínez-Climent JA; Montiel-Duarte C; Rifón J; Pérez-Calvo J; Arbona C; Prósper F; Pérez-Roger I
    Cancer Res; 2005 Apr; 65(8):3264-72. PubMed ID: 15833859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL.
    Sattler M; Salgia R
    Cytokine Growth Factor Rev; 1997 Mar; 8(1):63-79. PubMed ID: 9174663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia.
    Shuai K; Halpern J; ten Hoeve J; Rao X; Sawyers CL
    Oncogene; 1996 Jul; 13(2):247-54. PubMed ID: 8710363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation.
    Reuther JY; Reuther GW; Cortez D; Pendergast AM; Baldwin AS
    Genes Dev; 1998 Apr; 12(7):968-81. PubMed ID: 9531535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphatidylinositol 3-kinase p85{alpha} subunit-dependent interaction with BCR/ABL-related fusion tyrosine kinases: molecular mechanisms and biological consequences.
    Ren SY; Bolton E; Mohi MG; Morrione A; Neel BG; Skorski T
    Mol Cell Biol; 2005 Sep; 25(18):8001-8. PubMed ID: 16135792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells.
    Weisberg E; Banerji L; Wright RD; Barrett R; Ray A; Moreno D; Catley L; Jiang J; Hall-Meyers E; Sauveur-Michel M; Stone R; Galinsky I; Fox E; Kung AL; Griffin JD
    Blood; 2008 Apr; 111(7):3723-34. PubMed ID: 18184863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of anti-apoptotic pathways activated by BCR/ABL in the resistance of chronic myeloid leukemia cells to tyrosine kinase inhibitors.
    Danisz K; Blasiak J
    Acta Biochim Pol; 2013; 60(4):503-14. PubMed ID: 24273759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.